Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has results × eprenetapopt × Clear all

Phase

Phase 1/2 4 Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

Carboplatin 155 Cisplatin 153 Paclitaxel 152 Docetaxel 117 Cyclophosphamide 115 Dexamethasone 102 Doxorubicin 95 Bevacizumab 91 Gemcitabine 90 pembrolizumab 89 Rituximab 86 Prednisone 84 Fluorouracil 69 Pemetrexed 66 Vincristine 65 Radiotherapy 64 Etoposide 64 Nivolumab 59 Leucovorin 56 Capecitabine 56 Trastuzumab 54 Cytarabine 52 Methotrexate 44 Oxaliplatin 39 Lenalidomide 38 atezolizumab 37 Filgrastim 36 Irinotecan 34 Taxes 33 Sorafenib 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Aprea Therapeutics

Phase 3 Completed

154 enrolled 10 charts

MDS

Data powered by HemOnc (CC BY 4.0) Colophon ⚡